Richard Lafayette, MD
Nephrology · Stanford, CANPI 1922141951
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $344,171 of the $467,244 with a category attached, or 73.7%. It is spread thinly across 22 manufacturers, the largest accounting for just 20.0%. Among nephrology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $1488.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$93K
- Calliditas Therapeutics US Inc.$82K
- Novartis$74K
- Travere Therapeutics, Inc.$48K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$33K
- Biocryst Pharmaceuticals, Inc.$33K
- plus $104K from 16 others
Across 276 payments — averaging $9745.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$873K
- Beigene, Ltd.$770K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$289K
- Travere Therapeutics, Inc.$197K
- Beone Medicines Ltd.$125K
- Pfizer$112K
- plus $322K from 11 others
What the payments were for
- Consulting fees$344,17174%
- Speaking & faculty fees$34,8497%
- Travel & lodging$71,82515%
- Food & beverage$9,6562%
- Education$6,7441%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 54 | $93,349 |
| Calliditas Therapeutics US Inc. | 39 | $81,748 |
| Novartis | 48 | $74,142 |
| Travere Therapeutics, Inc. | 48 | $48,030 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 22 | $33,295 |
| Biocryst Pharmaceuticals, Inc. | 16 | $32,732 |
| GSK | 3 | $22,060 |
| Vertex | 20 | $21,099 |
| Amgen | 8 | $8,354 |
| Mallinckrodt Hospital Products Inc. | 8 | $8,023 |
| Beigene USA, Inc. | 12 | $7,180 |
| Aurinia Pharma U.S., Inc. | 9 | $6,964 |
| Omeros Corporation | 6 | $5,318 |
| Otsuka Pharmaceutical Co., Ltd. | 5 | $5,080 |
| ANI Pharmaceuticals, Inc. | 4 | $5,077 |
| Otsuka America Pharmaceutical, Inc. | 2 | $4,525 |
| Biogen | 2 | $3,500 |
| Pfizer | 2 | $3,336 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $1,830 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $1,280 |
| Apellis Pharmaceuticals, Inc. | 2 | $301 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$467,244 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 29 | $28,231 |
| EliquisApixaban | 28 | $19,514 |
| ProcritEpoetin Alfa | 11 | $16,115 |
| Envarsus XrTacrolimus | 11 | $8,831 |
| Tacrolimus | 35 | $7,265 |
| JardianceEmpagliflozin | 11 | $6,120 |
| Sevelamer Carbonate | 27 | $4,673 |
| NeoralCyclosporine, Modified | 13 | $4,077 |
| Mycophenolate Mofetil | 29 | $3,829 |
| Mycophenolic AcidMycophenolate Sodium | 13 | $1,398 |
| Nifedipine ErNifedipine | 18 | $1,392 |
| Amlodipine Besylate | 143 | $735 |
| Cinacalcet Hcl | 16 | $719 |
| Atorvastatin Calcium | 95 | $651 |
| Colchicine | 15 | $557 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $93,349 | $28,23129 claims |
| PfizerEliquis | $3,336 | $19,51428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,341 nephrology providers in California.
Other nephrology in Stanford
- Glenn ChertowStanford$2M
- Vivek BhallaStanford$78K
- Anjay RastogiLos Angeles$2.2M
- Luis AlvarezPalo Alto$1.8M
- Jose MorfinSacramento$1M
- Rodolfo BatarseRancho Mirage$910K
- Vandana MathurWoodside$769K
- Yasir QaziOrange$618K
- Rafael VillicanaLoma Linda$610K
- Sunil PatelApple Valley$509K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.